Dennis Charney
Professor of Psychiatry
Data updated
Research Footprint
Dennis Charney appears in 12 tracked papers (2000–2022), most studied alongside Ketamine and Placebo, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Antidepressant effects of ketamine in depressed patients (3831 citations).
Frequent co-authors: James Murrough, Daniel Iosifescu and Sanjay Mathew.
Publication Landscape
How the 12 papers Blossom tracks for Dennis Charney line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Dennis Charney's publishing grown?
SourcedTracked papers by publication year; 1 earlier paper published before 2008. Click a year for the running total.
Don't read as total output: only the 12 of 12 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Dennis Charney publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Dennis Charney publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Dennis S. Charney, MD, is a psychiatrist and clinical researcher whose work has focused on rapid-acting antidepressant treatments and the neurobiology of stress-related psychiatric disorders. He has led and contributed to multiple clinical trials investigating the antidepressant effects of intravenous ketamine in treatment-resistant major depression and chronic post-traumatic stress disorder, including two-site randomised controlled trials and repeated-dose administration studies. Charney's clinical research programme has concurrently examined neurocognitive effects of ketamine and sought neuroimaging correlates and predictors of treatment response, bridging clinical outcomes with mechanistic biomarkers.
His contributions emphasise rigorous clinical trial design for novel interventions, careful characterisation of cognitive and symptomatic effects, and integration of neuroimaging to identify potential predictors of response. Through these studies he has helped to define the therapeutic potential and limitations of repeated ketamine administration in severe mood and stress-related disorders and advanced translational approaches aimed at improving patient selection and mechanistic understanding of rapid antidepressant therapies.
Key Impact
A leading clinical investigator of intravenous ketamine for treatment-resistant depression and PTSD, recognised for conducting multi-site randomised controlled trials and translational neuroimaging studies that probe mechanisms and predictors of rapid antidepressant response.
Collaboration Network
25 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Dennis Charney's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Dennis Charney is associated with.
Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai in New York hosts the Parsons Research Center for Psychedelic Healing, founded by Rachel Yehuda, a psychiatrist known for three decades of work on PTSD and the biology of trauma. The centre grew out of a 2021 gift from the Bob and Renee Parsons Foundation and was expanded and renamed in 2024 with further funding and a purpose-built facility in Upper Manhattan. Working closely with the James J. Peters VA Medical Center in the Bronx, its researchers test MDMA-assisted therapy for veterans with PTSD and psilocybin for civilians, and are developing protocols for delivering MDMA within group psychotherapy. The programme pairs clinical trials with training designed to prepare therapists for supervised psychedelic-assisted care.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →Mount Sinai
hospitalThe Center for Psychedelic Psychotherapy and Trauma Research located at Mount Sinai and the James J. Peters Department of Veterans Affairs examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms. The Parsons Research Center for Psychedelic Healing has also recently opened at the Icahn School of Medicine at Mount Sinai.
View stakeholder →